

CURRICULUM VITAE

UDO S. GAIPL

PERSONAL DATA

Name Udo Sebastian Gaipl
Date / Place of Birth 23.01.1973 / Erlangen
Title Prof. Dr. rer. nat. habil.
Present Position Head of Radiation Immunobiology, Department of Radiation Oncology, Universitätsklinikum Erlangen, Germany
Citizenship German
Address Universitätsstraße 27, 91054 Erlangen, Germany
E-mail udo.gaipl@uk-erlangen.de
Phone / Fax +49 9131 85 – 44258 / +49 9131 85 – 39335

Education and Professional Experience

Present Position (since 01.10.2007) Head of Radiation Immunobiology, Department of Radiation Oncology, Universitätsklinikum Erlangen
since 2015 Professor for Experimental Medicine
2008/2009 Facultas docendi / Venia legendi for Experimental Medicine
2005-2007 Senior Researcher, Institute for Experimental Medicine I, FAU Erlangen-Nürnberg
2003 - 2005 PostDoc, EU-Project „APOCLEAR (QLK3-CT-2002-02017)“
Stay abroad in Milano, Hospitale San Raffaele, Clinical Immunology Unit
1999 - 2003 Scientific employee, Institute for Clinical Immunology, Medizinische Klinik 3, Friedrich-Alexander-Universität Erlangen-Nürnberg; Dr. rer. nat. (summa cum laude)

Professional Activities and Selected Scientific Awards

since 2020 Section Editor Radiation Biology of *Strahlentherapie und Onkologie* (Journal of Radiation Oncology – Biology – Physics)
since 2020 Academic Editor of *International Journal of Molecular Sciences*
since 2020 Editorial Board Member of *Radiation*
since 2018 Head of the AG Experimental Radiooncology of the DEGRO (Deutsche Gesellschaft für Radioonkologie)
2018 Author of Positioning Paper of the DEGRO on “Radiotherapy in Combination with Immunotherapy”
2018 Author of Practice Guidelines for Radiotherapy of Benign Diseases
since 2018 Board Member, ESHO (European Society for Hyperthermic Oncology)
since 2018 Board Member, DeGBS (German Society for Biological Radiation Research) e.V.

2016	Congress president of the 19th Annual Meeting of the Society for Biological Radiation Research – GBS e.V
2017	Awardee of the Ludwig-Zimmermann Award of the Department of Radiation Oncology of the Universitätsklinikum Erlangen
since 2013	Editorial Board of <i>International Journal of Hyperthermia</i>
2012	Topic Editor Frontiers in Immunology: “Radiation-induced effects and the immune system”
2010-2019	Commissioner of the DFG graduate school GRK1660
2005	Laureate of the 2005 award of the “Lupus Erythematoses Selbsthilfegemeinschaft e.V.”
2003	Summa cum laude (Dr. rer. nat.), Friedrich-Alexander-Universität Erlangen-Nürnberg
1997/1998	Awardee of the donation „Stipendien-Fonds des Verbandes der Chemischen Industrie e.V.“
1992-1997	Award for highly talented people according the “Bayerischen Begabtenförderungsgesetz (Bay BFG)”

Funding

since 2004	My research has been funded by the German Research Foundation (DFG), by the European Commission (FP6 and FP7), by the German Federal Ministry of Education and Research (BMBF), by the Bayerische Forschungsförderung, by the Doktor Robert Pflieger-Stiftung, and by the Thomas Wildey Institut
-------------------	--


Clinical Studies

since 2018	NCT03426657; <i>CheckRad-CD8</i> : Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC; Phase II study; Study Chair and Scientific Leader
since 2018	NCT03386357; <i>IMPORTANCE</i> : Radiotherapy With Pembrolizumab in Metastatic HNSCC, Phase II study; Study Chair and Scientific Leader
since 2018	EudraCT number: 2016-002085-31; <i>RAD-ON02</i> : Determining the immunological and pain reducing effects of serial radon balneology in patients with musculoskeletal disorders, Observational Study; Deputy Study Leader and Scientific Leader
Since 2017	NCT03453892; <i>ST-ICI</i> : Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition, Phase IV study; Scientific Leader
since 2016	NCT02653079; <i>IMMO-LDRT01</i> : Immunophenotyping From Blood of Patients Suffering From Chronic Degenerating Joint Diseases and Receiving LDRT, Phase II study; Deputy Study Leader and Scientific Leader
since 2015	NCT02600065; <i>GLIO-CMV-01</i> : Analysis of CMV Infections in Patients With Brain Tumors or Brain Metastases During and After Radio(Chemo)Therapy; Observational study; Deputy Study Leader and Scientific Leader
since 2015	NCT02528955; <i>DIREKHT</i> : De-Intensification Radiotherapy Postoperative Head Neck; Phase II study; Investigator
since 2015	NCT02369939; <i>HYCAN</i> : Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy; Phase II study; Investigator

- since 2013** NCT02022384; *IMMO-GLIO*: Immunophenotyping From Blood of Patients With Malignant Gliomas, Phase II study; Deputy Study Leader and Scientific Leader
- since 2013** NCT01827553; *CONKO-007*: Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy; Phase III trial; Investigator
- since 2013** EudraCT number: 2008-002130-30; *NSCLC-TKD/IL-2*: Targeted Natural Killer (NK) cell based adoptive immunotherapy for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC) after radiochemotherapy (RCT), Phase II study; Investigator
- 2013-2017** Ethical Approval BLÄK: 12131; *RAD-ON01*: Immunophenotyping of blood of patients with musculoskeletal disorders after Radon- and Radon/CO2 spa, Observational Study; Study Leader and Scientific Leader

Publications

- since 2000** 178 Peer-reviewed and PubMed-listed publications; h-index: 52; Scholar Link: https://scholar.google.de/citations?view_op=list_works&hl=de&user=yWTC71MAAAAJ



Erlangen, 06.07.2020

Udo Gaipf